![](https://cdn.sanity.io/images/0vv8moc6/onclive/fbf3bd7d1122fbf787aaffb2f5e5a8c79426a630-262x145.png?fit=crop&auto=format)
Dr Tolaney on the Development of Mutation-Selective PI3K Inhibitors in Breast Cancer
Sara M. Tolaney, MD, MPH, chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, associate director, Susan F. Smith Center for Women’s Cancers, senior physician, Dana-Farber Cancer Institute, associate professor, medicine, Harvard …